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Abstract. – From a dermatological aspect, it
posed a considerable challenge the skin-limited
form of mastocytosis, urticaria pigmentosa and
indolent systemic mastocytosis (ISM) with cuta-
neous lesions. Despite the favourable prognosis,
lifelong dermatological control is needed, during
which the average symptomatic therapy does
not always seem adequate.
We report here the case of a female ISM pa-
tient with recurrent cutaneous symptoms that
impaired her quality of life, with a follow-up time
of 27 years. During this long follow-up period,
the cutaneous lesions could be controlled by an-
tihistamines, leukotriene antagonists, glucocor-
ticoids, local immunosuppressants or local UV
radiation for only relatively short periods. Ima-
tinib mesylate was, therefore, introduced in an
attempt to control the cutaneous lesions. Tyro-
sine kinase inhibition is an unusual dermatologi-
cal therapeutic option.
This case illustrates that imatinib mesylate was
a good choice with which to achieve a reduction
of the skin lesions in this KIT D816V mutation-neg-
ative disease: it led to a temporary appreciable im-
provement of the patient’s quality of life.
Key Words:
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mastocytosis, KIT D816V mutation, Imatinib mesylate,
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Introduction
Systemic mastocytosis (SM) is a rare chronic
myeloproliferative neoplasm characterized by ab-
normal mast cell proliferation with accumulation
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in one or more extracutaneous organs1,2. The
2008 World Health Organization classification
defines various subtypes of SM, including indo-
lent SM (ISM), SM associated with a clonal non-
mast cell lineage disease (SM-AHNMD), aggres-
sive SM (ASM) and mast cell leukaemia1.
For dermatologists, considerable challenges
are posed by cutaneous mastocytosis without
bone marrow involvement as a skin-limited dis-
ease, and by ISM involving the bone marrow
with cutaneous symptoms. Though the masto-
cytes in ISM involve several organs, including
the bone marrow, it frequently presents clinically
with cutaneous symptoms alone or in combina-
tion with recurrent mediator-related systemic
symptoms (e.g. pruritus, flushing, diarrhoea and
headache)2. The life expectancy in ISM is more
favourable than in the other variants of SM: the
great majority of the patients have an almost nor-
mal life expectancy and a low disease progres-
sion rate. Nevertheless, the quality of life of these
patients can be severely affected by the mediator-
related systemic and/or cutaneous symptoms3.
The only therapeutic option for the specific cuta-
neous symptoms is symptomatic therapy: com-
monly antihistamines, leukotriene antagonists,
glucocorticoids, local immunosuppressants or lo-
cal UV radiation, and in selected special cases ty-
rosine kinase inhibitors (TKIs)2,4,5. The usefulness
of TKIs in SM has been actively investigated in re-
cent years, but the role of imatinib mesylate thera-
py in controlling the cutaneous lesions in ISM has
not been well established6-8.
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Figure 1. A, The diffuse brownish papular pruritic lesions
of this patient before the introduction of imatinib mesylate
treatment. B, A clear improvement of the skin lesions was
seen after imatinib mesylate treatment.
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Discussion
In recent years, TKIs, including imatinib, have
revolutionized the treatment of patients with
chronic myeloid leukaemia and gastrointestinal
stromal tumours9,10. Increasing evidence has
emerged to suggest that a small subset of SM pa-
tients who are KIT D816V-unmutated or who
have a very rare imatinib-sensitive KIT mutation
may also benefit from imatinib mesylate therapy,
which is presumed to reduce the mast cell media-
tor levels and results in an improvement in the
mediator-related symptoms6-8,11,12. In cases of SM
with eosinophilia, molecular investigation
(FIP1L1-PDGFRA rearrangement) is required, as
only patients with rearranged PDGFRA will re-
spond to imatinib therapy. Interestingly, KIT
D816V-mutated SM patients with eosinophilia
give no response13. The published data concern-
ing the effects of imatinib mesylate on the cuta-
neous lesions in ISM are still a matter of debate.
Only a small number of case reports in paediatric
diffuse cutaneous mastocytosis and in adult pa-
tients with cutaneous mastocytosis associated
This case report describes a female patient
with ISM who was followed up for 27 years, dur-
ing which the recurrent specific cutaneous symp-
toms frequently greatly impaired her quality of
life. Her case illustrates the potential value of
imatinib mesylate even in KIT D816V mutation-
negative ISM, with achievement of a temporary
improvement of the skin-related symptoms.
Case Presentation
The patient presented with diffuse brownish
papular lesions on the face, the trunk and the up-
per and lower extremities in 1986. Her lesions
regularly became red and elevated, with no obvi-
ous cause. The Darier sign was positive.
Histopathology of the skin biopsy confirmed the
diagnosis of mastocytosis.
The otherwise attractive young female patient
was highly disturbed by her skin symptoms,
which included itching, and the appearance of
her skin greatly influenced her quality of life.
She was treated first with antihistamines and
PUVA. However, because of the worsening of the
skin symptoms and the result of the bone marrow
biopsy, which confirmed ISM, interferon-alfa was
administrated in weekly doses of 2x3 million IU
for 1 year. This resulted in relief of her symptoms
for a period of 2 years, during which she was giv-
en only sodium-chromoglycate. Subsequently, in
consequence of the progression of her cutaneous
symptoms, repeated interferon-alfa therapy was
introduced in weekly doses of 3x3 million IU for
another year, which again resulted in the tempo-
rary relief of her symptoms. However, eosinophil-
ia and cutaneous progression shortly appeared
(Figure 1/a). As the recurring cutaneous symp-
toms, greatly disturbed the patient’s quality of life,
imatinib mesylate was introduced, even though
neither FIP1L1-PDGFRA gene rearrangement nor
a KIT D816V mutation nor any imatinib-sensitive
KIT mutation was present. Shortly after the begin-
ning of imatinib mesylate treatment her skin
symptoms improved, the lesions become macular
and the itching disappeared. She took imatinib
mesylate periodically between 2008 and 2010.
When the newly introduced imatinib treatment
first given a daily dose of 400 mg was commenced
for 6 months, which was followed by a daily dose
of 100 mg. She has currently been off imatinib for
more than 2 years, and although she still has
brownish macular lesions all over her body, the le-
sions do not interfere with her quality of life; she
needs antihistamine treatment only occasionally
(Figure 1/b).
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with chronic myelomonocytic leukaemia have
been found to demonstrate a marked improve-
ment following the administration of imatinib
mesylate7,14,15.
In light of the previously reported rare imatinib-
sensitive KIT mutations located in exons 9 and 11,
we screened our patient for the most frequently re-
ported KIT mutations in exons 9, 11 and 17, using
Sanger sequencing13. Although sequence analysis
did not reveal any KIT mutations in exon 17,
where the most common observed KIT D816V
mutation occurs and the other, though rare ima-
tinib-resistant mutations are mostly located, we
decided to introduce imatinib mesylate in an effort
to control the skin lesions. This case demonstrates
that imatinib mesylate therapy may be benefit,
even in KIT D816V-unmutated cases of ISM, re-
sulting at least temporarily in regression of the cu-
taneous symptoms.
Conclusions
Our case has revealed that imatinib mesylate
can be useful, even if with only a limited role, in
a KIT D816V-unmutated ISM patient with exten-
sive cutaneous involvement. When the cutaneous
lesions in ISM can no longer be controlled by an-
tihistamines, leukotriene antagonists, glucocorti-
coids, local immunosuppressants or local UV ra-
diation, imatinib mesylate may temporarily re-
duce the skin lesions and improve the quality of
life of the patient.
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